Marken, a pharmaceutical logistics provider, has expanded in China to meet the anticipated need for increased clinical trials logistics services. Marken has been granted a 12-year license to ship biological samples and drug product within China. In addition, Marken announced the start of its Phase II depot roll out plan as it has begun construction of its pharmaceutical depot at its new branch location near the Beijing International airport. Analysts predict that China clinical trials will grow at 20% over the next several years which will allow it to rival Japan and Korea as key hubs for pharmaceutical research and development. Marken stated it will continue to invest significantly in these countries to further enhance its base in Singapore, India, South Korea, Japan and Australia.